Lessons from Lumiracoxib: Are cyclooxygenase-2 inhibitors less hepatotoxic than non-selective non-steroidal anti-inflammatory drugs?

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 6, 2012, Pages 993-994

  Chitturi, Shivakumar ^a   Farrell, Geoffrey C ^a  

^a Canberra Hospital   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BROMFENAC; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; GLUTATHIONE; IBUPROFEN; LEUKOCYTE ANTIGEN; LUMIRACOXIB; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLBUTAZONE; ROFECOXIB; SULINDAC; VALDECOXIB;

ACUTE HEPATITIS; ACUTE LIVER FAILURE; AMINOTRANSFERASE BLOOD LEVEL; CARDIOTOXICITY; CHOLESTASIS; CHOLESTATIC HEPATITIS; CHRONIC HEPATITIS; EDITORIAL; GASTROINTESTINAL MUCOSA; GENETIC ASSOCIATION; GRANULOMATOUS HEPATITIS; HOSPITALIZATION; HUMAN; LIVER INJURY; LIVER TOXICITY; LIVER TRANSPLANTATION; OSTEOARTHRITIS; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; SKIN ALLERGY; STEVENS JOHNSON SYNDROME; TOXIC HEPATITIS;

EID: 84861473232     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2012.07142.x     Document Type: Editorial

References (13)

1. Pillans PI, Ghiculescu RA, Lampe G, Wilson R, Wong R, Macdonald GA. Severe acute liver injury associated with lumiracoxib. J. Gastroenterol. Hepatol. 2012; 27: 1102-5.
2. Li Y, Slatter JG, Zhang Z etal. In vitro metabolic activation of lumiracoxib in rat and human liver preparations. Drug Metab. Dispos. 2008; 36: 469-73.
3. Kang P, Dalvie D, Smith E, Renner M. Bioactivation of lumiracoxib by peroxidases and human liver microsomes: identification of multiple quinoneimine intermediates and GSH adducts. Chem. Res. Toxicol. 2009; 22: 106-17.
4. Singer JB, Lewitzky S, Leroy E etal. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat. Genet. 2010; 42: 711-14.
5. Chitturi S, Farrell GC. Identifying who is at risk of drug-induced liver injury: is human leukocyte antigen specificity the key? Hepatology 2011; 53: 358-62.
6. Bessone F. Non-steroidal anti-inflammatory drugs: what is the actual risk of liver damage? World J. Gastroenterol. 2010; 16: 5651-61.
7. Fontana RJ, McCashland TM, Benner KG etal. Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. The Acute Liver Failure Study Group. Liver Transpl. Surg. 1999; 5: 480-4.
8. La Grenade L, Lee L, Weaver J etal. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. Drug Saf. 2005; 28: 917-24.
9. Traversa G, Bianchi C, Da Cas R, Abraha I, Menniti-Ippolito F, Venegoni M. Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ 2003; 327: 18-22.
10. El Hajj II, Malik SM, Alwakeel HR, Shaikh OS, Sasatomi E, Kandil HM. Celecoxib-induced cholestatic liver failure requiring orthotopic liver transplantation. World J. Gastroenterol. 2009; 15: 3937-9.
11. Papachristou GI, Demetris AJ, Rabinovitz M. Acute cholestatic hepatitis associated with long-term use of rofecoxib. Dig. Dis. Sci. 2004; 49: 459-61.
12. Laine L, White WB, Rostom A, Hochberg M. COX-2 selective inhibitors in the treatment of osteoarthritis. Semin. Arthritis Rheum. 2008; 38: 165-87.
13. Lee CH, Wang JD, Chen PC. Increased risk of hospitalization for acute hepatitis in patients with previous exposure to NSAIDs. Pharmacoepidemiol. Drug Saf. 2010; 19: 708-14.